Europe
A shortage of qualified personnel may be a drag factor in cell and gene therapies; in China 100,00L of capacity will need to be added every year to meet bio demand
uniQure N.V. announced the publication of 26-week interim data from the ongoing Phase IIb clinical trial of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B, in the journal, Blood Advances.
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
As the third quarter of 2019 comes to an end, most biopharma companies are reporting their earnings as they head into the final lap for the year. Here’s a look at some of the bigger companies’ reports that came out this week.
Novartis is careful to note that Cosentyx showed “numerically higher results versus Humira,” and that there are some statistically significant advantages of the drug over Humira.
ObsEva SA announced that the U.S. Food and Drug Administration has allowed the Company to begin enrolling patients in IMPLANT 3, the U.S pivotal Phase 3 clinical trial of nolasiban in women undergoing embryo transfer following in-vitro fertilization.
Further German cooperation with the Paracelsus Clinic in Zwickau and first NanoTherm treatment center outside of Germany opened at the Independent Public Clinical Hospital No. 4 (SPKS4) in Lublin, Poland
Martinsried/ Munich Medigene AG announces its participation at the following upcoming scientific and investor conferences.
Centrient Pharmaceuticals, the global leader in the production and commercialisation of sustainable antibiotics, next generation statins and anti-fungals, is proud to announce it has received a Gold Sustainability rating from EcoVadis.
Scientists have shown how measles causes long-term damage to the immune system, leaving people vulnerable to other infections.
PRESS RELEASES